Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.
Pharmacogenomics
; 24(16): 859-870, 2023 Nov.
Article
en En
| MEDLINE
| ID: mdl-37942634
ABSTRACT
Aim:
Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. Materials &methods:
A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System.Results:
25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio 7.9; 95% CI 1.1-56; p = 0.0394).Conclusion:
Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Farmacogenética
/
Pruebas de Farmacogenómica
Límite:
Humans
Idioma:
En
Revista:
Pharmacogenomics
Asunto de la revista:
FARMACOLOGIA
/
GENETICA MEDICA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos